Keywords: b-ms, baraclude, shows, efficacy, hcv, trial, pharmaceutical

B-MS' Baraclude shows efficacy in HCV trial

Article | 05 June 2006

Print This

US pharmaceutical firm Bristol-Myers Squibb says that data from a 96-week clinical trial of its drug Baraclude (entecavir), a nuceloside ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in